Table 1.
Baseline mean (SD) demographic and clinical characteristics by sex.
| Men (n = 93) | Women (n = 51) | p value | Effect size | |
|---|---|---|---|---|
| Age | 30.5 (11.6) | 33.8 (14.4) | 0.157 | 0.261 |
| Diagnosis: schizophrenia | 54/93 (58%) | 30/51 (59%) | 1.000 | 0.015 |
| Diagnosis: schizotypal | 2/93 (2%) | 0/51 (0%) | 0.539 | 0.294 |
| Diagnosis: Delusional disorder | 13/93 (14%) | 8/51 (16%) | 0.975 | 0.048 |
| Diagnosis: Brief psychotic disorder | 14/93 (15%) | 4/51 (8%) | 0.323 | 0.229 |
| Diagnosis: Schizo-affective | 2/93 (2%) | 8/51 (16%) | 0.004* | 0.520 |
| Diagnosis: Other | 0/93 (0%) | 1/51 (2%) | 0.354 | 0.281 |
| Diagnosis: Unspecified | 8/93 (9%) | 0/51 (0%) | 0.051 | 0.595 |
| Antipsychotic-naive | 36/93 (39%) | 20/51 (39%) | 1.000 | 0.055 |
| Smoking | 56/93 (60%) | 29/51 (57%) | 0.753 | 0.068 |
| Abuse/dependence—alcohol | 10/93 (11%) | 3/51 (6%) | 0.374 | 0.178 |
| Abuse/dependence—drugs | 24/93 (26%) | 3/51 (6%) | 0.003* | 0.578 |
| PANSS total | 78.1 (15.6) | 79.1 (16.6) | 0.704 | 0.063 |
| PANSS positive | 21.2 (4.90) | 21.3 (4.60) | 0.844 | 0.021 |
| PANSS negative | 17.8 (5.80) | 17.8 (6.70) | 0.992 | 0.000 |
| PANSS general | 39.1 (8.90) | 40.0 (8.10) | 0.535 | 0.104 |
| Neurologic side effects | 0.70 (0.60) | 0.50 (0.50) | 0.183 | 0.353 |
| Sexual side effects | 0.48 (0.42) | 0.33 (0.61) | 0.177 | 0.303 |
| BMI (kg/m2) | 25.1 (4.70) | 26.5 (7.80) | 0.268 | 0.234 |
| Glucose (mmol/L) | 5.40 (1.40) | 5.20 (0.90) | 0.303 | 0.160 |
| Prolactin (mIU/L) | 290.3 (195.9) | 467.8 (499.2) | 0.021 | 0.529 |
Data are n (%) or mean (SD). Differences significant with α = 0.05 are shown in bold. p Values with asterisk (*) remained significant after FDR correction. Cohen’s d was used for mean values and Cohen’s h was used for proportions.
n number in the sample, antipsychotic-naive no previous exposure to antipsychotic drugs, PANSS Positive and Negative Syndrome Scale, BMI body mass index.